NVCR

10.7100.19%
KG

Kinyip Gabriel Leung

Independent Director

Mr. Kinyip Gabriel Leung, also known as Gabe, served as an Executive Vice President of OSI Pharmaceuticals Inc. since May 21, 2003. Mr. Leung served as the President of Pharmaceutical Business of OSI Pharmaceuticals Inc. since June 2009. His initial responsibilities included developing and implementing OSI Pharmaceuticals Inc.'s commercial strategy, including developing a high-quality unit to support marketing, sales and business development. He initially led a re-launch of Novantrone(R) for cancer uses in the U.S., and upon the pending closing of OSI Pharmaceuticals Inc.'s acquisition of Cell Pathways, Gelclair(TM). Mr. Leung served as the President of Oncology Business of OSI Pharmaceuticals Inc. since April 2005, where he served as the Chief Business Officer for its oncology and diabetes/obesity therapeutic areas prior to its purchase by Astellas. During his 22-year career in the pharmaceutical and biotech industry, Mr. Leung has extensive experience in commercial product launch, business development, marketing, sales, medical affairs and business operations in global pharmaceutical and biotech organizations. He served as Group Vice President of Global Prescription Business at Pharmacia Corporation and Head, successful Pharmacia Global Oncology franchise. Prior to Pharmacia, Mr. Leung served as marketing executive in Bristol-Myers Squibb's oncology business. He headed OSI Pharmaceuticals Inc.'s Global Oncology Franchise, where his responsibilities included medical affairs, marketing and sales worldwide in over 80 countries. He orchestrated two new product launches and helped build one of the strongest oncology pipelines in the industry through acquisition and in-licensing. From 1991 to 1999 Mr. Leung was at Bristol-Myers Squibb Company (BMS) where he led the growth of Taxol(R) and Paraplatin(R) into the then number one and number two chemotherapeutic agents in the United States and widened the lead for BMS Oncology as the leading oncology franchise. Prior to this, Mr. Leung gained worldwide business development experience at the Eastman Kodak Company and Sterling Drug, Inc. He served as the Chairman of the Global Commercialization Team of NovoCure Limited since October 5, 2011. He served as the Chairman of Delcath Systems, Inc. from September 2013 to September 2014 and its Director from March 2011 to December 11, 2014. He served as a Director of Albany Molecular Research Inc. from November 2010 to February 4, 2016. Mr. Leung served as a Director of NanoMed Pharmaceuticals, Inc., since May 22, 2007. He is a collaborating partner of the National Dialogue on Cancer, a national initiative. Under this initiative, He co-chairs a special task force to design a new Research and Development paradigm to help expedite oncology drug discovery and development. He has been Independent Director of NovoCure Limited since October 5, 2011 and served as its Vice Chairman since October 05, 2011. He is also vice-chair of the Life Sciences Consortium. He serves as an advisor to the NCI Director. He is an active member of C-Change. He serves as a member of the National Cancer Institute Clinical Trial Advisory Committee (NCI CTAC). Mr. Leung is a pharmacist and trained at the University of Texas at Austin where he earned his B.S. degree with High Honors. He attended graduate school at the University of Wisconsin-Madison where he earned his M.S. degree in Pharmacy, with concentration in pharmaceutical marketing.

Positions